Literature DB >> 37873

Diuretics as initial treatment for essential hypertension.

F A Finnerty.   

Abstract

1 In the United States, the thiazide diuretics are considered the cornerstone of all antihypertensive regimens for four reasons: by themselves, they are capable of controlling the blood pressure in 60-70% of the hypertensive population; they prevent the sodium retention produced by all other antihypertensive agents; they can be given once a day; and they are inexpensive. 2 Despite these advantages, the thiazide do cause hypokalaemia hyperuricaemia and hyperglycaemia. The incidence of hypokalaemia (K less than 3.0 mEq/l) is only 2-4%; the incidence of hyperuricaemia (uric acid greater than 10 mg per cent is 3-4%; and the incidence of hyperglycaemia is 1-2%. 3 The possibility that a beta-blocking agent combined with a thiazide diuretic might produce better BP control, prevent thiazide-induced abnormalities and exert a coronary prevention action with once daily administration would suggest that such a combination should be the ideal initial therapy for most patients with hypertension.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 37873      PMCID: PMC1429330          DOI: 10.1111/j.1365-2125.1979.tb04689.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

Review 1.  Clinical pharmacology of antihypertensive drugs.

Authors:  A S Nies
Journal:  Med Clin North Am       Date:  1977-05       Impact factor: 5.456

2.  FLUID RETENTION PRODUCED BY GUANETHIDINE; CHANGES IN BODY EXCHANGEABLE SODIUM, BLOOD VOLUME, AND CREATININE CLEARANCE.

Authors:  A J SMITH
Journal:  Circulation       Date:  1965-04       Impact factor: 29.690

3.  Methyldopa in the treatment of hypertension.

Authors:  R I BAYLISS; E A HARVEY-SMITH
Journal:  Lancet       Date:  1962-04-14       Impact factor: 79.321

4.  Methyldopa in hypertension. Clinical and pharmacological studies.

Authors:  C T DOLLERY; M HARINGTON
Journal:  Lancet       Date:  1962-04-14       Impact factor: 79.321

Review 5.  Hypertension, antihypertensive drugs and atherosclerosis.

Authors:  W Hollander
Journal:  Circulation       Date:  1973-11       Impact factor: 29.690

6.  Aldosterone excretion. Physiological variations in man measured by radioimmunoassay or double-isotope dilution.

Authors:  J E Sealey; F R Bühler; J H Laragh; E L Manning; H R Brunner
Journal:  Circ Res       Date:  1972-09       Impact factor: 17.367

7.  The effect of beta adrenergic blockade on patterns of urinary sodium excretion. Studies in normal subjects and in patients with heart disease.

Authors:  S E Epstein; E Braunwald
Journal:  Ann Intern Med       Date:  1966-07       Impact factor: 25.391

8.  Severe hypertension. Treatment with minoxidil.

Authors:  P K Mehta; B Mamdani; R M Shansky; S D Mahurkar; G Dunea
Journal:  JAMA       Date:  1975-07-21       Impact factor: 56.272

9.  The effects of oxprenolol (Trasicor, Ciba 39089-Ba) on patterns of urinary sodium excretion in man.

Authors:  B N Singh; M R Till; D T Kelly
Journal:  Am J Cardiol       Date:  1971-04       Impact factor: 2.778

10.  Increase in serum-lipids during treatment of hypertension with chlorthalidone.

Authors:  R P Ames; P Hill
Journal:  Lancet       Date:  1976-04-03       Impact factor: 79.321

View more
  4 in total

Review 1.  The management of hypertension.

Authors:  B N Prichard; C W Owens
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

Review 2.  Drug treatment of hypertension.

Authors:  B N Prichard
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  A study of the antihypertensive action of xipamide using ambulatory intra-arterial monitoring.

Authors:  E B Raftery; D I Melville; B A Gould; S Mann; J R Whittington
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

4.  Piretanide, a potassium stable diuretic, in the treatment of essential hypertension.

Authors:  M Verho; B Rangoonwala; W Dols; U Fratzer; J Kaczynski; W Mühlhäusler
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.